Canadian biologics CMO BioVectra has been contracted to make trial supplies of the candidate cancer treatment Prolanta by US biopharmaceutical firm Oncolix.
UK based contract API maker Aesica Pharmaceuticals has been granted a Home Office license to make controlled substances at its facility in Cramlington, Northumberland.
ethica Clinical has added biomarker data analysis technology to its roster of services in a C$1.25m (€782,899) deal with fellow Canadian CRO Matrix Pharma.
Ampac Fine Chemicals (AFC) has added three new commercial-scale Hastelloy liquid-liquid centrifuges to its API making business in a move that, it says, will increase batch size and lower manufacturing costs.
US CMO Florida Biologix (FB) says its new contract with America Stem Cell (ASC) shows that demand for trial-phase biologics manufacturing is starting to recover.
Novasep’s API manufacturing facility in Le Mans, France has been certified under the potent compound safety programme run by occupational health and safety specialist SafeBridge Consultants.
UK API maker and contract manufacturing organization (CMO) Aesica Pharmaceutical has landed a multi-year deal to produce and package drugs on behalf of Amdipharm.
US investment group JLL has described Lonza’s rival offer for Patheon as “a hostile attempt to adversely impact [the Canadian contractor’s] competitive position.”
Pharmaceutical and cosmetics contract manufacturing organisations (CMOs) in India can now claim tax credit on their advertising spend following a recent appeal court victory for US beverage giant Coca-Cola.
Cobra Biomanufacturing’s new Adenovirus manufacturing and process services contract is further evidence of the health of EU biologicals market, according to business development manager Philip Ridley-Smith.
Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon Holdings.
Cambrex has posted a positive set of Q2 results, recording an operating income of $9m (€6.3m), but warned that the second half of the year is likely to be down on the corresponding six months of last year.
In the latest twist in an increasing bitter takeover battle, the Ontario Superior Court of Justice has rejected JLL’s bid to oust directors elected to the board of Canadian CMO Patheon in April.
Swiss life sciences solutions firm Lonza has been contracted by US biotechnology group Elusys Therapeutics to produce Anthim, its late stage Ab candidate treatment for anthrax infection.
Ireland’s API manufacturing sector suffered a blow on Friday with Corden Pharmachem’s announcement that it is phasing-out manufacturing at its facility in Little Island, Cork.
Fine chemicals firm Minakem believes that manufacturing capacity added by its newly acquired API plant in Dunkirk, France will reduce costs and help it compete on a global scale.
US drug firms’ qualification of overseas API vendors will be subject to increased FDA scrutiny in the coming years according to a new industry report by analysts Hogan & Hartson (H&H).
Althea Technologies’ biologics and injectables contract development, manufacturing and testing facility in San Diego, US is open for business, bringing to an end the firm’s two year campaign to expand capacity.
Patheon chief Wes Wheeler says the drop in Q1 losses the firm recently reported is due to the “restructuring activities and rigorous cost containment efforts” it enacted towards the end of last year.
Halo Pharmaceuticals hopes that its acquisition of Abbott Laboratories’ 200,000 sq ft formulation, manufacturing and warehousing facility in Whippany, New Jersey will help it blossom into a CMO and development organisation.
To accompany the map detailing job losses, which can be viewed here, we have picked out the details and trends from the data, uncovering the state of US pharmaceutical employment in 2008.
One of Actavis’ Bulgarian production facilities is being bought out by the management, which will provide contract manufacturing services to the generic maker and other companies.
Life sciences firm DSM has landed the contract to manufacture supplies of NicOx’ much vaunted anti-inflammatory agent naproxcinod and looks good for the long term deal.
Following Barack Obama’s victory in the race to the White House, in-PharmaTechnologist.com examines what this could mean for the pharmaceutical industry.
China’s WuXi PharmaTech has reported a below par set of unaudited third quarter results and has cut its full-year expectations blaming the current economic climate’s impact on R&D spending within the sector.
Pfizer is shifting its research focus to those diseases where its sees the potential for the biggest treatment improvements and profits, while dropping eight disease areas including cholesterol.
Haupt Pharma has completed its merger with fellow German companies Amareg and Wülfing Pharma to create a major new force in the European contract development and manufacturing sector, with around 1,500 staff and an annual turnover of €180m.
US-based DSM Biologics and MorphoSys are teaming up to manufacture the MOR202 antibody, which has shown considerable promise as a treatment for multiple myeloma (MM).
Sanofi Aventis has extended its deal with China’s NovaMed, adding the anti-convulsant Depakine (valproic acid) to the latter firm’s distribution roster.
Lonza of Switzerland is reaping the benefit of a shift away from bulk chemicals and towards custom manufacturing of high-value pharmaceuticals with a 13 per cent hike in sales in the first half of the year.
The pace of change at GlaxoSmithKline (GSK) is showing no sign of slowing, with new CEO Andrew Witty unveiling the company’s new strategic direction with the release of second quarter results.
Contract research and production specialist Patheon is to promote
BSP Pharmaceuticals' cytotoxic development and manufacturing
services as part of a marketing agreement that the two firms have
signed.
Introgen Therapeutics says advances in its biologics manufacturing
and storage technologies have allowed it to broaden the scope of
its contract manufacturing operations and set up a new unit called
Introgen Technical Services (ITS).
Pharmaceutical manufacturers are now withdrawing from manufacturing
at an unprecedented rate, with four of the top 10 players
announcing major new outsourcing programmes in 2007, says IMS in a
new document which explores the implications...
SynCo Bio Partners has completed production of AG011 for ActoGenIX,
enabling the latter firm to begin examining it in patients
suffering from ulcerative colitis (UC).
Bushu Pharmaceuticals, Japan's largest dedicated contract
manufacturer, has been going from strength to strength as Japan's
pharma outsourcing industry awakens.
2005 marked the real beginning of contract manufacturing in Japan,
which had been held back by an overly-cautious regulatory
environment and significant and unique quality and specification
demands in the marketplace.
Agilent's purchase of DowPharma's Nucleic Acid Medicines business
is the second time in recent years that the US scientific
measurements specialist has ramped-up its nucleic acid
manufacturing capabilities.
Cambrex has experienced a jump in profitability for the first
quarter 2008, despite a decrease in sales, assisted by previous
cost-cutting initiatives.
US drug giant Pfizer plans to close or sell off an additional 13
manufacturing facilities as part of an effort to cut its number of
production plants to 44 by the end of 2009.
GEA Pharma Systems' Collette unit will present Consigma, its new
continuous high shear granulation and drying system, at the
Interpack exhibition in Düsseldorf later this month.
Overall, 2007 was another stellar year for contract service
providers, particularly those at the early-stage end of
development, although companies are advised to watch out for a
tougher environment ahead.
Stiefel Laboratories, Biopharm Services, Multisorb Technologies,
the Pharmaceutical Research and Manufacturers of America, Catalent
Pharma Solutions and Chromatide have all had people on the
move in the world of pharmaceutical manufacturing.
India's Jubilant Organosys has made good on promises to make
acquisitions in the contract research and manufacturing services
(CRAMS) sector with a $255m deal to buy Draxis Health of Canada.
Solvents are defined as organic chemicals that are used to dissolve components. They are used during the manufacture of drug substances and can also potentially...
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...